biomedicina slovenica


pr=Bruning : 7

  1. Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Čufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ
    Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study
    2003
  2. Biganzoli Laura; Čufer Tanja; Bruning Peter; Coleman Robert E; Duchateau Luc; Rapoport Bernardo; Nooij Marianne; Delhaye Francois; Miles D; Sulkes Aaron
    Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial
    2003
  3. Biganzoli L; Čufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
    Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European organization for research and treatment of cancer 10961 multicenter phase III trial
    2002
  4. Biganzoli L; Čufer T; Bruning P; Coleman R; Calvert H; Gamucci T; Twelves C; di Paola E Donato; Duchateau L; Yague C
    Doxorubicin (A) / Taxol (T) versus doxorubicin /cyclophosphamide (C) as first line chemotherapy in metasttaic breast cancer (MBC): a phase III study
    2000
  5. Therasse P; Mauriac L; Welnicka M; Bruning P; Čufer T; Lichinitser R; Pluzanska A; Tomiak E; Koopmanschap M; Piccart M
    The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study: results of an EORTC-NCIC-SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC)
    1999
  6. Therasse P; Mauriac L; Welnicka M; Bruning P; Čufer T; Tomiak E; Curran D; Ramirez A; Koopmanschap M; Piccart M
    An EORTC-NCIC-SAKK neoadjuvant randomized phase III study comparing CEF (5FU, epirubicin, cyclophosphamide) vs dose intensified EC+G-CSF (filgrastim) in locally advanced breast cancer (LABC): updated results including quality of life
    1998
  7. Therasse P; Mauriac L; Welincka M; Bruning P; Čufer T; Bonnefoi H; Tomiak E; Hamilton A; Piccart M
    Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer (LABC): an EORTC-NCIC-SAKK randomized phase 3 study comparing FEC (5FU, epirubicin, cyclophosphamide) VS high dose intensity EC + G-CSF (filgrastim)
    1998


New search      Comments      Top of page Institute for Biostatistics and Medical Informatics